VERU INC. Logo

VERU INC.

Biopharma firm developing drugs for cardiometabolic and inflammatory diseases.

VERU | US

Overview

Corporate Details

ISIN(s):
US92536C1036
LEI:
Country:
United States of America
Address:
2916 N. MIAMI AVENUE, 33127 MIAMI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Veru Inc. is a late clinical-stage biopharmaceutical company dedicated to developing and commercializing novel treatments for cardiometabolic and inflammatory diseases. The company's pipeline is primarily focused on enobosarm, an oral selective androgen receptor modulator (SARM) designed to preserve muscle in patients undergoing weight loss therapy with GLP-1 drugs, thereby promoting higher-quality weight loss. Veru is also advancing sabizabulin, a novel oral anti-inflammatory agent for the treatment of atherosclerotic coronary artery disease. In addition to its cardiometabolic focus, the company has also developed therapies for oncology and viral-induced acute respiratory distress syndrome (ARDS).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all VERU INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for VERU INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for VERU INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.